[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dyspepsia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dyspepsia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,49,81,113,142,180,207,237,259,283,312,335,362,390,410,436,467,488,508,534,555],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100534619","phase-4-famotidine-and-antacids-for-treatment-of-dyspepsia-100534619",false,"NCT06241183","Famotidine and Antacids for Treatment of Dyspepsia","Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department","Inclusion Criteria:\n\n1. Subject Age ≥ 18 years of age\n2. Patient diagnosed with dyspepsia\n3. Present at the ED with upper abdominal pain score of at least 3\n\nExclusion Criteria:\n\n1. Hypersensitivity to an ingredient in Maalox\u002F Mylanta or Famotidine\n2. Moderate to Severe Renal Insufficiency (precaution)\n3. Kidney Failure\n4. Pregnant or Nursing\n5. Verbal pain score less than 3\n6. Inability to tolerate oral medications\n7. Bowel Obstruction\n8. Proton pump inhibitor within 2 hours of study treatment","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox\u002F Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.",[26,27,28],"Dyspepsia","GERD","Acid Reflux",[30,27,28,31,32,33,34,35],"dyspepsia","H2 receptor antagonist","antacid","Maalox","Mylanta","Famotidine","RECRUITING","2026-06-01",{"date":39,"type":40},"2026-06-02","ACTUAL",{"date":42,"type":40},"2023-11-09",{"date":44,"type":20},"2027-12-31",{"name":46,"class":47},"Stony Brook University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100637154","phase-4-effect-of-digestive-enzymes-as-add-on-therapy-on-patients-with-functional-dyspepsia-100637154","NCT07578402","Effect of Digestive Enzymes as Add on Therapy on Patients With Functional Dyspepsia.","Effect of Digestive Enzymes as Add on Therapy on Patients With Functional Dyspepsia - A Randomised, Open Label Trial","Inclusion Criteria:\n\n* Age 18 years or more\n* Patients with FD diagnosed according to ROME IV criteria\n\nExclusion Criteria:\n\n* Structural lesion in endoscopy and positive H. pylori status\n* History of malignancy, liver and biliary tract disease, diabetes mellitus, chronic kidney disease, thyroid disorders\n* Psychiatric disorders\n* Previous history gastrointestinal surgery\n* Any history of hypersensitivity, adverse effect, or ineffectiveness with digestive enzyme\n* Pregnancy and breastfeeding.",true,"70 Years",{"count":59,"type":20},120,[23],"The goal of this clinical trial is to assess the effect of digestive enzymes in improving dyspeptic symptoms in patients with functional dyspepsia. It will also assess about the safety of drug by recording the patient reported adverse events. The main questions it aims to answer are:\n\nDoes drug digestive enzymes has any effect on patients with functional dyspepsia? What medical problems do participants have when taking drug digestive enzymes? Researcher will compare drug digestive enzymes to a control group taking standard first line treatment only.\n\nParticipants will:\n\nTake drug digestive enzymes 325 milligrams 3 times daily, every day for 4 weeks along with standard first line treatment. A second group will be taken as control arm who will be kept on standard first line treatment only for 4 weeks. They will visit the hospital 2 weekly, and their symptoms will be assessed by a 5-point Likert Scale at baseline, week 2 and 4. Additionally, patient reported adverse events will be documented.",[26,63,64,65],"Functioanl Dyspepsia","Epigastric Pain Syndrome","Epigastric Fullness",[26,67,68,69,70],"Post parendial distress syndrome (PPDS)","Epigastric pain syndrome (EPS)","Functional dyspepsia (FD)","Disorder of gut brain interaction (DGBI)","NOT_YET_RECRUITING","2026-05-05",{"date":74,"type":40},"2026-05-11",{"date":76,"type":20},"2026-05-15",{"date":78,"type":20},"2027-02-28",{"name":80,"class":47},"Rakibul Mostafa",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100634280","phase-4-vonoprazan-based-versus-esomeprazole-based-triple-therapy-for-helicobacter-pylori-eradication-100634280","NCT07537634","Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication","Comparison Between Vonoprazan-Based Triple Therapy and Esomeprazole-Based Triple Therapy for Eradication of Helicobacter Pylori Infection: An Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Dyspeptic patients with positive for both rapid urease test and stool antigen test\n3. Patients giving written informed consent\n\nExclusion Criteria:\n\n1. Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study\n2. Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study\n3. Previous H. pylori eradication therapy\n4. Gastric or duodenal ulcer with current or recent bleeding on endoscopy\n5. Significant upper or lower gastrointestinal bleeding within 4 weeks\n6. Patients with regular intake of NSAIDs or steroids\n7. Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy\n8. Known case of malignancy, including MALToma\n9. Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease)\n10. Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months\n11. Pregnant, lactating woman or intend to become pregnant within the study period\n12. History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and\u002For levofloxacin\n13. On colchicine\n14. Subjects with abnormal laboratory test at the start of the screening period:\n\nS. creatinine \\> 2 mg\u002Fdl SGPT \\> 2 x Upper limit of normal",{"count":19,"type":20},[23],"The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.\n\nThe main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.\n\nResearchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.\n\nParticipants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.\n\nFour weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.\n\nDrug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.\n\nParticipants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.",[92,26,93,94,95],"Helicobacter Pylori Infection","Peptic Ulcer Disease","Helicobacter Pylori","H Pylori",[97,98,99,100,101,102,26],"Helicobacter pylori","Helicobacter pylori eradication","Vonoprazan","Esomeprazole","Levofloxacin","Triple therapy","2026-04-18",{"date":105,"type":40},"2026-04-22",{"date":107,"type":20},"2026-04-15",{"date":109,"type":20},"2026-08-14",{"name":111,"class":47},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",2,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":48},"100185996","phase-3-domperidone-in-treating-patients-with-gastrointestinal-disorders-100185996","NCT01696734","Domperidone in Treating Patients With Gastrointestinal Disorders","Treatment Protocol for the Compassionate Use of Domperidone","Inclusion Criteria:\n\n* Patients with GI disorders who have failed standard therapy\n* Symptoms or manifestations of: a) gastroparesis; b) refractory gastroesophageal reflux disease (GERD) including persistent esophagitis, refractory heartburn, reflux-related laryngitis, and respiratory symptoms; or c) severe dyspepsia\n* Completion of a comprehensive evaluation, including clinical history and physical examination, to eliminate other causes of their symptoms\n* Patient has signed the informed consent document agreeing to the use of the study drug, domperidone\n* White blood cell (WBC) with differential greater than 3,000\u002Fml\n* Alkaline phosphatase less than 1.5 x upper limit of normal\n* Alanine aminotransferase (ALT) less than 2 x upper limit of normal\n* Aspartate aminotransferase (AST) less than 2 x upper limit of normal\n* Bilirubin less than or equal to 2 x upper limit of normal\n* Blood urea nitrogen (BUN) less than 2 x upper limit of normal\n* Creatinine less than 1.5 x upper limit of normal\n* Stable hemoglobin greater than or equal to 8.0 g\u002Fdl\n* Potassium between range of 3.0 to 5.5\n* Magnesium level between 1.6-2.6 mg\n\nExclusion Criteria:\n\n* Patients with the following cardiac diagnoses: ventricular tachycardia or fibrillation; Torsade des Pointes; clinically significant bradycardia; sinus node dysfunction; heart block; prolonged QTc interval (QTc \\> 450 milliseconds for males, QTc \\> 470 milliseconds for females); prior specific cardiovascular conditions of clinically significant valvular heart disease requiring medication, ischemic, or pulmonary heart disease; cardiomyopathy; history of heart failure\n* Patients who are receiving antiarrhythmic medications with action on repolarization times (with prolongation of the QTc interval such as amiodarone, disopyramide, dofetilide, flecainide, ibutilide, quinidine, sotalol, dronedarone etc.)\n* Patients who are receiving monoamine oxidase (MAO) inhibitors\n* Patients with a history of or active liver failure\n* Clinically significant electrolyte disorders including sodium \\\u003C 130 or \\> 145 and\u002For potassium \\\u003C 3.0 or \\> 5.5 and\u002For magnesium \\\u003C 1.6 or \\> 2.6\n* GI hemorrhage or obstruction experienced within the previous 6 weeks\n* Presence of a prolactinoma (prolactin-releasing pituitary tumor)\n* Pregnant or breast-feeding female (women of childbearing potential \\[WOCBP\\], defined as not post-menopausal for 12 months or without previous surgical sterilization, must have a negative urine pregnancy test within 30 days of the first administration of domperidone and must either commit to continued abstinence from heterosexual intercourse or use an effective method of birth control during the course of the study)\n* Known allergy to domperidone","16 Years",{"count":122,"type":20},200,[124],"PHASE3","This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.",[127,26,128,129,130,131,132],"Digestive System Disorder","Esophagitis","Gastroesophageal Reflux Disease","Gastroparesis","Heartburn","Nausea and Vomiting","2026-04-10",{"date":135,"type":40},"2026-04-13",{"date":137,"type":40},"2012-10-23",{"date":139,"type":20},"2027-10-31",{"name":141,"class":47},"M.D. Anderson Cancer Center",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":48},"100632230","symptoms-and-quality-of-life-in-patients-with-heterotopic-gastric-mucosa-hgm-100632230","NCT07510984","Symptoms and Quality of Life in Patients With Heterotopic Gastric Mucosa (HGM)","Prevalence and Characterization of Dysphagia and Dyspepsia Symptoms and Assessment of Quality of Life in Heterotopic Gastric Mucosa (HGM)","SYM-HGM","Inclusion Criteria:\n\n* Planned upper gastrointestinal endoscopy (gastroscopy) for clinical reasons (any indication)\n* Age ≥ 18 years\n* Written informed consent\n* Ability to complete the study questionnaires prior to endoscopy\n\nExclusion Criteria:\n\n* Previously known heterotopic gastric mucosa (HGM)\n* Previously diagnosed dysphagia with prior therapeutic intervention (including pre-established diet modification, partial oral\u002Fenteral nutrition, steroid therapy, botulinum toxin injection, etc.)\n* Mechanical ventilation\n* Presence of a tracheostomy\n* Inadequate endoscopic assessability of the proximal esophagus, including:\n* General condition insufficient for careful endoscopic inspection (investigator's judgement)\n* Increased risk of aspiration\n* Inadequate visibility during the procedure (e.g., bleeding, food residue)\n* Complications preventing careful inspection of the proximal esophagus\n* History of surgery involving the pharynx or esophagus\n* Relevant severe neurological disorder (e.g., ALS, stroke)\n* Severe dementia\n* Severe depressive disorder\n* Lack of cooperation \u002F inability to comply with study procedures\n* Planned PEG placement\n* Emergency endoscopy",{"count":151,"type":20},721,"OBSERVATIONAL","The goal of this observational study is to learn whether heterotopic gastric mucosa (HGM) in the upper esophagus is associated with swallowing difficulties (dysphagia) in adults undergoing a medically indicated gastroscopy. The main questions it aims to answer are:\n\n* Is the presence of HGM associated with dysphagia?\n* Is the presence of HGM associated with dyspepsia and reduced health-related quality of life? Among participants reporting dysphagia, what is the distribution of oropharyngeal versus esophageal dysphagia, and is this related to the presence of HGM? If there is a comparison group: Researchers will compare participants with endoscopically confirmed HGM to participants without HGM to determine whether dysphagia, dyspepsia symptoms, and quality-of-life measures differ between groups.\n\nParticipants will:\n\nComplete pseudonymised questionnaires about dysphagia, dyspepsia symptoms, and quality of life before the gastroscopy.\n\nUndergo the medically indicated gastroscopy as planned; the endoscopist will assess whether HGM is present based on the endoscopic appearance, and routine endoscopy findings will be documented.",[155,156,157,26],"Heterotopic Gastric Mucosa of the Proximal Esophagus","Gastric Inlet Patches","Dysphagia",[159,160,161,162,163,164,165,166,167,168,169,170],"Cervical Esophagus","Proximal Esophagus","Upper Endoscopy","Oropharyngeal Dysphagia","Eophageal Dysphagia","Sidney Swallowing Questionnaire","EAT-10","MDADI","GSRS","QOLRAD","Narrow Band Imaging","Quality of Life","2026-04-09",{"date":173,"type":40},"2026-04-14",{"date":175,"type":40},"2026-03-24",{"date":177,"type":20},"2027-07",{"name":179,"class":47},"Knappschaft Kliniken GmbH",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":189,"conditions":190,"keywords":193,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":4},"100628196","predicting-peptic-complications-using-h-pylori-serology-and-gastric-ultrasound-100628196","NCT07458490","Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound","H. Pylori Serology and Gastric Ultrasound Findings in Predicting Peptic Complications","Inclusion Criteria:\n\n* Adult patients (age ≥18 years) presenting with dyspeptic symptoms (epigastric pain, nausea, vomiting, heartburn).\n* Patients with suspected or confirmed peptic ulcer disease.\n* Patients presenting with acute complications (hematemesis, melena, acute - abdominal pain suggestive of perforation).\n* Patients with history of peptic ulcer disease requiring surveillance.\n* Patients who provide informed consent.\n\nExclusion Criteria:\n\n* Previous gastric surgery (gastrectomy, vagotomy).\n* Active malignancy (gastric cancer, lymphoma).\n* Previous H. pylori eradication therapy within 4 weeks.\n* Current use of proton pump inhibitors (PPIs) within 2 weeks (may affect antibody levels and ultrasound findings).\n* Severe coagulopathy or bleeding disorders (INR \\>2.0).\n* Pregnancy.\n* Poor quality ultrasound images due to excessive bowel gas or obesity.\n* Hemodynamically unstable patients requiring immediate intervention.\n* Refusal to participate in the study.",{"count":188,"type":20},230,"This observational study aims to evaluate whether combining a simple blood test (H. pylori serology) with a non-invasive abdominal ultrasound can accurately predict severe complications in patients with peptic ulcer disease (PUD). Peptic ulcer complications, such as stomach bleeding or perforation, are serious and typically require an invasive procedure called an upper endoscopy for diagnosis and treatment.\n\nResearchers want to find out if these two non-invasive tests can be used together to create a reliable risk-scoring system. This system would help doctors quickly identify which patients are at a high risk for complications and need an urgent endoscopy, compared to those who are at a lower risk and can be safely monitored without the invasive procedure.\n\nThe study will include adult patients presenting with stomach symptoms (like pain, nausea, or heartburn), as well as those with suspected or confirmed peptic ulcer disease. Participants will provide a blood sample to check for H. pylori antibodies and undergo a standard, painless abdominal ultrasound to examine the thickness of their stomach wall. An upper gastrointestinal endoscopy will be performed if it is clinically necessary as part of the patient's standard medical care.",[93,191,92,192,26],"HELICOBACTER PYLORI INFECTIONS","Peptic Ulcer",[194,195,196,93,92,197,26],"H. pylori serology","gastric ultrasound","peptic complications","Peptic Ulcer Complications","2026-03-04",{"date":200,"type":40},"2026-03-09",{"date":202,"type":20},"2026-04",{"date":204,"type":20},"2027-05",{"name":206,"class":47},"Assiut University",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":215,"targetDuration":217,"studyType":152,"phases":4,"briefSummary":218,"conditions":219,"keywords":225,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":48},"100432993","functional-digestive-disorders-observatory-100432993","NCT04918329","Functional Digestive Disorders Observatory","Observatory of Functionnal Digestive Disorders","OTFI","Inclusion Criteria:\n\n* Patients over 18 years of age;\n* Patients with functional digestive disorder for more of 3 months;\n* Patients assessed as part of routine care;\n* Patients affiliated to the Social Security ;\n* Patients not opposed to participation in the Centre\n\nExclusion Criteria:\n\n* Person deprived of liberty by administrative or judicial decision or major protected subject (under guardianship or curatorship);\n* Patients unable for any reason to read, understand, respond questionnaires (visual, psychiatric, cognitive, etc.)",{"count":216,"type":20},2000,"10 Years","Functional digestive pathologies are defined by symptoms such as functional dyspepsia, gastroesophageal reflux, irritable bowel syndrome, gastroesophageal reflux, functional constipation, functional diarrhea, functional bloating, the opioid-induced constipation and fecal incontinence, without organic substratum. These diseases are very common in the general population (20%) and represent the first cause of consultation in city gastroenterology. The pathophysiology of these functional disorders is complex and often multifactorial: disturbances in digestive motility, altered visceral sensitivity, sphincter dysfunction, post-surgery, intestinal inflammation, dysbiosis, and impairment of the gut-brain axis. For example, it has been shown that one in four patients with inflammatory bowel disease in confirmed remission report digestive symptoms consistent with a functional bowel disorder, suggesting a possible pathophysiological continuum between these two conditions.\n\nThe objective of this study is to collect prospective clinical and tests data and a biological collection from biological samples (digestive biopsies, blood, urine and fecal samples) collected as part of the standard care. This collection could identify diagnostic or prognostic markers of the therapeutic response.",[220,26,221,222,223,224],"Irritable Bowel Syndrome","Functional Constipation","Faecal Incontinence","Abdominal Pain (AP)","Vomiting Syndrome",[226,227],"Observatory","functional digestive disorders","2026-01-05",{"date":230,"type":40},"2026-01-08",{"date":232,"type":40},"2020-10-09",{"date":234,"type":20},"2030-10-09",{"name":236,"class":47},"University Hospital, Rouen",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100613906","effect-of-h-pylori-eradication-on-the-improvement-of-gastrointestinal-symptoms-100613906","NCT07272681","Effect of H. Pylori Eradication on The Improvement of Gastrointestinal Symptoms","Effect of Helicobacter Pylori Eradication on Gastrointestinal Symptoms in Adult Patients","HPE-GI","Inclusion Criteria:\n\n1. Adults aged 18 years and older.\n2. Confirmed diagnosis of Helicobacter pylori infection by one or more diagnostic tests.\n3. Presence of any upper or lower gastrointestinal symptoms.\n4. Willingness to undergo H. Pylori eradication therapy and follow-up.\n5. Ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Age less than 18 years.\n2. The previously unsuccessful application of empirical H. pylori eradication therapy.\n3. Use of non-steroidal anti-inflammatory drugs (NSAIDs).\n4. Any malignant disease of the stomach or any other site.\n5. Any associated comorbidity (renal insufficiency, mental illness).\n6. History of allergies to proton pump inhibitors or antibiotics.\n7. Refusal to participate in the survey.",{"count":246,"type":20},100,"This study aims to evaluate the effect of Helicobacter pylori eradication on gastrointestinal symptoms in adult patients. H. pylori infection is a common cause of dyspepsia and other upper gastrointestinal complaints. The trial will assess whether successful eradication therapy leads to significant improvement in symptoms compared to baseline. Adult patients diagnosed with H. pylori infection will receive standard eradication treatment, and symptom changes will be monitored using validated questionnaires over a defined follow-up period.",[92,26,249],"Gastrointestinal Symptoms","2025-12-08",{"date":252,"type":40},"2025-12-16",{"date":254,"type":20},"2025-12-20",{"date":256,"type":20},"2026-12-20",{"name":258,"class":47},"Amany Usama Ahmed Arafa",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":21,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":48},"100603657","phase-4-saccharomyces-boulardii-combined-with-bismuth-quadruple-therapy-for-helicobacter-pylori-rescue-treatment-100603657","NCT07139366","Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment","Efficacy and Safety of Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18\\~75, both gender.\n* Patients who had failed H.pylori eradication therapies .\n* Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.\n\nExclusion Criteria:\n\n* Patients who have previously used tetracycline and furazolidone antibiotics to eradicate infection with H. pylori.\n* Contraindications to study drugs.\n* Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.\n* Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within 2 weeks before the \\[13C\\] urea breath test), antibiotics or bismuth complexes (more than 3 times \u002F1 month before screening).\n* Pregnant or lactating women.\n* Underwent upper gastrointestinal Surgery.\n* Dysphagia.\n* Evidence of bleeding or iron efficiency anemia.\n* A history of malignancy.\n* Drug or alcohol abuse history in the past 1 year.\n* Systemic use of corticosteroids, non steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg\u002Fd).\n* Mental disorder.\n* Enrolled in other clinical trials in the past 3 months.\n* Refuse to sign informed consent.","75 Years",{"count":268,"type":20},1248,[23],"This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuth#esomeprazole#tetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.",[272,26,92,273,192],"Gastritis","Gastric Cancer","2025-11-30",{"date":276,"type":40},"2025-12-02",{"date":278,"type":40},"2025-10-28",{"date":280,"type":20},"2026-09",{"name":282,"class":47},"Yongquan Shi",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":294,"conditions":295,"keywords":298,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":112},"100613026","the-difference-in-carbon-footprint-between-diagnostic-upper-gi-endoscopy-in-dyspeptic-patients-versus-therapeutic-upper-gi-bleeding-100613026","NCT07261228","The Difference in Carbon Footprint Between Diagnostic Upper GI Endoscopy in Dyspeptic Patients Versus Therapeutic Upper GI Bleeding","THE DIFFERENCE IN CARBON FOOTPRINT BETWEEN DIAGNOSTIC UPPER GI ENDOSCOPY IN DYSPEPTIC PATIENTS VERSUS THERAPEUTIC UPPER GI BLEEDING","Inclusion Criteria:\n\n* Patients with dyspepsia or non-variceal upper GI bleeding\n* Age 20-80 years\n* Body mass index of 30 or less;\n* Receiving one of the following procedure during upper GI endoscopy:\n\nFor diagnostic endoscopy: Rapid urease test for H. pylori infection For therapeutic endoscopy: stop bleeding with either Argon plasma coagulation or Bipolar hemostasis probe or Hemostasis clip\n\nExclusion Criteria:\n\n* Platelet \\\u003C 50,000\n* INR \\> 2.5\n* Pregnancy\n* History of allergy to IV sedative medication\n* Peptic ulcer grade IIc and III according to Forrest classification\n* Patient receiving inhalation anesthesia","20 Years","80 Years",{"count":293,"type":20},75,"The goal of this observational study is to learn about the carbon footprint produced from diagnostic upper GI endoscopy in patients with dyspepsia and therapeutic upper GI endoscopy in patients with non-variceal upper GI bleeding. The main question it aims to answer is:\n\n• How much carbon footprint is generated from upper GI endoscopy Participants are already receiving diagnostic and therapeutic upper GI endoscopy as part of their regular medical care for dyspepsia and non-variceal upper GI bleeding, respectively. The carbon footprint generated from this treatment process is examined.",[296,26,297],"Carbon Footprint in Upper GI Endoscopy","Non-variceal Upper Gastrointestinal Bleeding",[299,300,301,26,302],"Carbon footprint","Upper GI endoscopy","EGD","Non-variceal upper gastrointestinal bleeding","2025-11-21",{"date":305,"type":40},"2025-12-03",{"date":307,"type":40},"2025-06-01",{"date":309,"type":20},"2025-12-31",{"name":311,"class":47},"King Chulalongkorn Memorial Hospital",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":291,"enrollmentInfo":319,"targetDuration":4,"studyType":21,"phases":320,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":334},"100544505","visible-abdominal-distension-100544505","NCT06369753","Visible Abdominal Distension","Tratamiento de la distensión Abdominal Funcional","Inclusion Criteria:\n\n* episodes of visible abdominal distension triggered by meal ingestion\n\nExclusion Criteria:\n\n* organic cause detected by clinical work-up\n* constipation\n* abdominal distension not confirmed by the 7-day clinical questionnaires in the pre- intervention evaluation",{"count":246,"type":20},[321],"NA","Background. Abdominal distention is produced by an abnormal somatic postural tone. The authors developed an original biofeedback technique. In a randomized, placebo-controlled trial the authors demonstrated the superiority of biofeedback over placebo for the treatment of abdominal distention. However, the technique is technically complex and unpractical.\n\nAim. To prove the efficacy of a noninstrumental biofeedback technique, transmitted by a standard training program, for the treatment of abdominal distension in different centers.\n\nSelection criteria. Episodes of visible abdominal distension. Intervention. Patients will be randomized into biofeedback and placebo groups. Three sessions of either biofeedback or placebo intervention will be performed during the first 3 weeks of the intervention period.\n\nBiofeedback: Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. In each center one operator will receive a standard training on how to deliver the noninstrumental biofeedback treatment. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.\n\nPlacebo: Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.",[220,26,324],"Functional Bloating","2025-10-30",{"date":327,"type":40},"2025-10-31",{"date":329,"type":40},"2025-07-30",{"date":331,"type":20},"2026-10",{"name":333,"class":47},"Hospital Universitari Vall d'Hebron Research Institute",7,{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":360,"locationsCount":48},"100484368","exposure-based-cbt-for-avoidantrestrictive-food-intake-in-functional-dyspepsia-100484368","NCT05587127","Exposure-Based CBT for Avoidant\u002FRestrictive Food Intake in Functional Dyspepsia","A Randomized Controlled Trial of Exposure-Based Cognitive Behavioral Treatment for Avoidant\u002FRestrictive Food Intake in Functional Dyspepsia","Inclusion Criteria\n\n* Age at least 18 years at screening visit\n* Rome IV Functional Dyspepsia post-prandial distress type (with or without epigastric pain syndrome)\n* Negative upper endoscopy or upper radiographic GI series to rule out structural\u002Forganic cause for FD\n* Avoidant\u002FRestrictive Food Intake Disorder (ARFID) diagnosis (by the Structured Clinical Interview for DSM-5; SCID-5 at Screening visit)\n* ≥5% weight loss from weight after functional dyspepsia symptom onset (at Screening visit)\n* Stable for outpatient care (based on the American Psychiatric Association Practice Guideline for the Treatment of Patients with Eating Disorders)\n* No previous history of CBT for functional dyspepsia or ARFID\n* Computer\u002Finternet webcam access\n* Fluency in English\n* Stable dose for 30 days if on any medication\n\nExclusion Criteria\n\n* Inability to provide informed consent\n* Presence of other conditions that could explain the patient's symptoms by chart:\n\nPyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT) Active H.pylori infection (by CLO test or stool antigen test) Active inflammatory bowel disease Eosinophilic gastroenteritis or eosinophilic esophagitis Acute renal failure Chronic renal failure (serum creatinine \\>3 mg\u002FdL) and\u002For on hemodialysis or peritoneal dialysis Acute liver failure Any acute gastrointestinal process Any plausible structural or metabolic causes Heartburn as predominant symptom History of peptic ulcer\n\n* Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed)\n* History of gastrointestinal tract surgery (including gastrectomy, gastric bypass surgery, and small or large bowel resection)\n* History of any serious medical condition (e.g., cancer)\n* Use of narcotic analgesics greater than three days per week\n* Current pregnancy or breastfeeding within the last 8 weeks\n* Uncontrolled diabetes (indicated by HbA1c ≥7%) by chart\n* Intellectual disability by history\n* Current substance\u002Falcohol use disorder within the past month\n* Current\u002Fhistory of psychosis (by Mini-International Neuropsychiatric Interview (MINI-Screen)\n* Current mania (by Mini-International Neuropsychiatric Interview (MINI-Screen) (defined as any manic episodes within the past 12 months)\n* Active suicidal ideation (by MINI-Screen)\n* Psychiatric disorder that would warrant independent attention (by Mini-International - Neuropsychiatric Interview (MINI-Screen))\n* Current enteral or parenteral feeding\n* Plans to initiate another psychotherapy or pregnancy in the concurrent study period",{"count":343,"type":20},50,[321],"Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant\u002Frestrictive food intake disorder (ARFID) with weight loss.",[347,26,348,349,350,351,352,353],"Avoidant\u002FRestrictive Food Intake Disorder","Feeding and Eating Disorders","Cognitive Behavioral Therapy","Appetite Regulation","Functional Dyspepsia","Post-prandial Distress Syndrome","Behavioral Medicine","2025-09-22",{"date":356,"type":40},"2025-09-25",{"date":358,"type":40},"2022-11-30",{"date":204,"type":20},{"name":361,"class":47},"Massachusetts General Hospital",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":370,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":21,"phases":374,"briefSummary":375,"conditions":376,"keywords":377,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":48},"100586016","a-study-of-chios-mastic-water-in-dyspepsia-100586016","NCT06909890","A Study of Chios Mastic Water in Dyspepsia","The Effectiveness of a Natural Aqueous Extract of Chios Mastic in the Management of Dyspepsia: the MASTIQUA-D Randomized Controlled Clinical Trial","MASTIQUA-D","Inclusion Criteria:\n\n* Age 30-60 years old.\n* Body mass index of 20-35 kg\u002Fm2.\n* Presence of dyspepsia.\n\nExclusion Criteria:\n\n* Presence of chronic diseases (e.g. diabetes mellitus, cancer, cardiovascular, hepatic, renal, respiratory, chronic inflammatory and psychiatric diseases).\n* Presence of other chronic gastrointestinal diseases (e.g. gastroesophageal reflux, inflammatory bowel disease and celiac disease).\n* Use of immunosuppressants, anti-inflammatories, antibiotics and corticosteroids.\n* Use of dietary supplements or other products with Chios mastic.\n* Excessive alcohol consumption (\\>210 g and \\>140 g of ethanol per week for men and women, respectively).\n* Currently on a weight-loss diet or recent (within 6 months) significant change in lifestyle habits.\n* Pregnancy or breast feeding (for women)","30 Years","60 Years",{"count":373,"type":20},60,[321],"Chios mastic is a natural product with strong antimicrobial, anti-inflammatory and antioxidant properties, and well-established benefits for dyspeptic disorders. The aim of the present study is to investigate the effectiveness of a natural aqueous extract of Chios mastic (mastic water), a by-product of Chios mastic processing, in the management of dyspepsia. This will be a 3-month randomized double-blind controlled clinical trial in adults with dyspepsia. Participants will be blindly randomized to an intervention group, which will receive 600 mL\u002Fd of a carbonated beverage enriched with Chios mastic water (0.2%), or a control group, which will receive 600 mL\u002Fd of an identical placebo beverage with no active ingredients. Participants will be evaluated in terms of anthropometric indices, lifestyle habits, severity of dyspepsia-related gastrointestinal symptoms, quality of life, as well as biochemical markers, both pre- and post-intervention.",[26],[378,379,30,380],"Pistacia Lentiscus var. Chia","Chios mastic","gastrointestinal health","2025-09-09",{"date":383,"type":40},"2025-09-15",{"date":385,"type":40},"2025-07-10",{"date":387,"type":20},"2026-12",{"name":389,"class":47},"Harokopio University",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":291,"enrollmentInfo":397,"targetDuration":4,"studyType":21,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":48},"100588449","high-resolution-gastric-mapping-and-gastroduodenal-manometry-100588449","NCT06941545","High Resolution Gastric Mapping and Gastroduodenal Manometry","An Assessment of Gastrointestinal Function Utilizing High Resolution Gastric Mapping, Gastroduodenal Manometry, and Gastric Emptying Testing With Assessment of Acute Response to Transcutaneous Auricular Vagal Nerve Stimulation.","Inclusion Criteria\n\n* Symptoms consistent with functional dyspepsia as defined by the ROME IV criteria for 6 months\n* Ability to perform appropriate informed consent\n\nExclusion Criteria\n\n* Known cardiac arrhythmia or major ECG abnormalities, i.e. cardiac conduction disturbances (2nd or 3rd degree AV block, prolonged QTc interval (\\> 460 msec) or bradycardia (\\\u003C 45 beats\u002Fminute)\n* Conditions precluding safe use of taVNS\n* Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and\u002For pose safety concerns\n* Use of opioids\n* Vulnerable study population\n* Pregnant women",{"count":246,"type":20},[321],"Dyspepsia is a common problem attributed to gastric sensorimotor dysfunctions ie, delayed, or less frequently rapid gastric emptying (GE), impaired gastric accommodation, and increased gastric sensation. Therapeutic options manage symptoms, and there is no FDA approved medical therapy for dyspepsia. There is a need for better objective understanding of sensorimotor dysfunction in dyspepsia, as well as noninvasive, efficacious, safe, and inexpensive treatments for dyspepsia.\n\nThe purpose of this research is to identify disturbances and characterize phenotypes in patients with functional dyspepsia, and to assess the correlations between symptoms (during the manometry and in daily life), gastric emptying, electrical activity (BSGM), and pressure activity (manometry).",[26],"2025-08-13",{"date":403,"type":40},"2025-08-19",{"date":405,"type":40},"2025-07-11",{"date":407,"type":20},"2026-12-31",{"name":409,"class":47},"Mayo Clinic",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":4},"100574224","exocrine-pancreatic-insufficiency-and-functional-dyspepsia-100574224","NCT06756503","Exocrine Pancreatic Insufficiency and Functional Dyspepsia","Prevalence and Clinical Characteristics of Exocrine Pancreatic Insufficiency in Patients With Functional Dyspepsia","Inclusion Criteria:\n\n* Patients over 18 years of age diagnosed with functional dyspepsia based on Rome IV criteria, who have been excluded for organic, metabolic, and medication-related causes (NSAIDs), and who test negative for H. pylori.\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Organic diseases of the digestive tract (celiac disease, inflammatory bowel diseases, neoplasms, positive for H. pylori)\n* Uncontrolled systemic diseases (diabetes mellitus, hypo- or hyperthyroidism, cancer, etc.)\n* Lack of informed consent\n* Severe psychiatric disorders, defined based on the DSM-5","65 Years",{"count":419,"type":20},65,"The goal of this observational study is to learn about the prevalence of exocrine pancreatic insufficiency in patients with functional dyspepsia .\n\n. The main questions it aims to answer are: What is the prevalence of exocrine pancreatic insufficiency (EPI) in patients with functional dyspepsia? Wich are the clinical characteristics associated with (EPI) in patients with functional dyspepsia? Patients diagnosed with functional dyspepsia will undergo an evaluation of clinical symptoms and fecal elastase determination. In those with fecal elastase levels below 100 µg\u002Fg, an endoscopic ultrasound and other assessments will be performed to define the cause of exocrine pancreatic insufficiency (EPI).",[422,26],"Exocrine Pancreatic Insufficiency",[424,425,426],"Exocrine pancreatic insufficiency","Functional dyspepsia","Fecal elastase","2025-08-05",{"date":429,"type":40},"2025-08-08",{"date":431,"type":20},"2025-09-01",{"date":433,"type":20},"2026-08-01",{"name":435,"class":47},"Maria Marta Piskorz",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":442,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":444,"conditions":445,"keywords":452,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":48},"100574160","a-prospective-multicentre-real-world-assessment-of-the-efficacy-of-danning-tablets-in-alleviating-digestive-symptoms-100574160","NCT06755671","A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms","Inclusion Criteria:\n\n* Patients between 18 and 75 years old\n* Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation\n* Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia\n* Patients agree to sign the informed consent form\n\nExclusion Criteria:\n\n* Past history or comorbidity of malignant tumor\n* Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases\n* Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)\n* Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician\n* Pregnancy or breastfeeding\n* Participation in other clinical trials within the past 3 months\n* Other circumstances determined as ineligible by the research physician",{"count":443,"type":20},4500,"The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation.\n\nThe main questions it aims to answer are:\n\nHow effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients?\n\nParticipants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.",[446,26,447,448,449,450,451,351],"Indigestion","Bloating","Loss of Appetite","Reflux Acid","Constipation","Upper Abdominal Pain",[453,30,454,455,456],"Danning Tablets","indigestion","observational study","real world study","2025-05-13",{"date":459,"type":40},"2025-05-14",{"date":461,"type":40},"2025-04-30",{"date":463,"type":20},"2027-06-30",{"name":465,"class":466},"Shanghai Hutchison Pharmaceuticals Limited","INDUSTRY",{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":291,"enrollmentInfo":473,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":475,"conditions":476,"keywords":477,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":487},"100548519","epidemiological-investigation-of-helicobacter-pylori-infected-patients-and-the-effect-of-eradication-treatment-on-dyspepsia-symptoms-100548519","NCT06422052","Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms","Inclusion Criteria:\n\n* Male or female patients aged 18-80 years\n* H. pylori infection diagnosed by 13C\u002F 14C-UBT (\\> 2 times the cutoff value) and\u002For gastroscopy (rapid urease strong positive and histological positive)\n* Treatment-naive patients with Helicobacter pylori\n* Ability and willingness to participate in the study and to sign and give informed consent\n\nExclusion Criteria:\n\n* Under 18 or over 80 years old\n* Organic digestive diseases, such as active peptic ulcer, gastroesophageal reflux, gastrointestinal bleeding, acute\u002Fchronic pancreatitis, acute\u002Fchronic cholecystitis, gallstones, intestinal obstruction, inflammatory bowel disease, etc.\n* Combined with melena, hematemesis, anemia, emaciation and other alarm symptoms\n* Pregnant and lactating women\n* History of cancer\n* History of subtotal gastrectomy\n* Severe organ dysfunction of heart, liver, kidney, lung and other important organs and congenital diseases, such as grade IV heart failure, liver failure, uremia, respiratory failure, hemophilia, Wilson's disease, etc.",{"count":474,"type":20},2242,"The objectives of this multicenter, prospective, observational study were to investigate the incidence of dyspeptic symptoms in patients with Helicobacter pylori (H. pylori) infection and to continuously follow up the remission of dyspeptic symptoms after H. pylori eradication, so as to provide reference for the clinical diagnosis and treatment strategies of patients with H. pylori infection and dyspeptic symptoms.",[92,26],[92,26],"2024-12-26",{"date":480,"type":40},"2024-12-30",{"date":482,"type":40},"2024-03-11",{"date":484,"type":20},"2025-05-31",{"name":486,"class":47},"Shanghai Jiao Tong University School of Medicine",26,{"id":489,"slug":490,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":496,"conditions":497,"keywords":498,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":48},"100502544","the-clinical-course-and-factors-for-the-progression-of-uninvestigated-dyspepsia-to-functional-dyspepsia-100502544","NCT05823636","The Clinical Course and Factors for the Progression of Uninvestigated Dyspepsia to Functional Dyspepsia","Inclusion Criteria:\n\n* Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.\n\nExclusion Criteria:\n\n1. Patients with local or systemic diseases which may cause dyspeptic symptoms:\n\n   Known active peptic ulcer, cholecystitis, gallstone, gastrointestinal obstruction, gastroparesis, and etc.\n2. Known acute or chronic injury of liver or kidney\n3. Obvious hematological abnormality, or endocrine and metabolic diseases\n4. Known malignancy; Obvious cardiovascular or cerebrovascular diseases (such as coronary heart disease, arrhythmia, cerebral infarction and etc.\n5. Other conditions which may be associated with dyspeptic symptoms (such as NSAIDs associated dyspepsia)\n6. organ failure defined by Marshall standard or severe psychiatric illnesses\n7. pregnancy or lactation\n8. unable to provide consent",{"count":495,"type":20},220,"Dyspepsia is one of the most common gastrointestinal diseases. This disease was defined as predominant epigastric pain lasting for at least 1 month, which can be accompanied with other symptoms, such as epigastric fullness, and early satiety. Despite dyspepsia symptoms lasting for ≥1 month represented clinical problem, a longer duration of 6 months or more after first-onset symptom was required for the diagnosis of functional dyspepsia based on ROME IV criteria. It was unclear about the natural procession of first-onset dyspepsia to functional dyspepsia assessed by Rome IV or Asia criteria and possible factors associated with this progression.",[26],[351,499],"uninvestigated dyspepsia","2024-09-24",{"date":502,"type":40},"2024-09-26",{"date":504,"type":40},"2023-01-01",{"date":309,"type":20},{"name":507,"class":47},"Air Force Military Medical University, China",{"id":509,"slug":510,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":56,"sex":16,"minAge":515,"maxAge":516,"enrollmentInfo":517,"targetDuration":4,"studyType":21,"phases":519,"briefSummary":520,"conditions":521,"keywords":523,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":4},"100559809","clinical-study-of-de-stress--happy-gut-powder-for-stress-and-indigestion-in-adults-100559809","NCT06568965","Clinical Study of De-Stress & Happy Gut Powder for Stress and Indigestion in Adults.","A Randomized, Double-blind, Placebo-controlled, Parallel Arm Clinical Trial of De-Stress and Happy Gut Powder in Relieving Stress and Functional Dyspepsia Symptoms in Adults.","Inclusion Criteria:\n\n1. Male and female participants aged 21-50 years both inclusive\n2. Suffering from self-reported mild to moderate stress on the PSS scale score less than or equal to 26\n3. Participants willing to participate in clinical trials and who have read understood and signed the informed consent form\n4. No severe anxiety and depression i.e. Generalized anxiety disorder GAD score less than or equal to 10 and Patients' health questionnaire-9 PHQ-9 score less than or equal to 14\n5. Diagnosis of functional dyspepsia\u002Fnon-ulcer dyspepsia by fulfilling Rome-III criteria\n6. Participant should be suffering with at least 4 or more symptoms mentioned below and with a total symptom score of 20 or more based on a 7-point Likert scale (a) Upper abdominal fullness (b) Upper abdominal pain (c) Belching (d) Bloating (e) Early satiety (f) Nausea (g) Vomiting (h) Regurgitation (i) Heartburn (j) Loss of appetite\n\nExclusion Criteria:\n\n1. Inability to perform any of the assessments required for endpoint analysis\n2. Known hypersensitivity to investigational products\n3. Participants with a history of substance abuse, drugs, heavy use of alcohol, and\u002For smoking within last 5 years\n4. Advanced chronic illness that would impair follow-up or monitoring\n5. Participants who have used dietary supplements, medications, such as oral\u002FIV antibiotics or probiotics, or supplements known to affect hunger, satiety, appetite, or gut microbiome within three months prior to recruitment. Additionally, individuals currently using nutraceuticals, allopathic, or ayurvedic supplements for stress and or gastrointestinal health management;\n6. Participants suffering from abdominal obesity that is waist circumference of more than 80 cm in females and of more than 90 cm in male;\n7. Pregnant or lactating women, as well as women of childbearing potential who are not using contraception or intending to conceive during the study\n8. Participants with current or past diagnoses of peptic ulcer disease, gastroesophageal reflux disorder (GERD), or irritable bowel syndrome (IBS), as well as those who have undergone surgery related to these conditions\n9. Have any other neurodegenerative diseases, mental illness or dementia\n10. Any other clinical condition in the judgment of investigator finds the study participation unsuitable for the participant.","21 Years","50 Years",{"count":518,"type":20},81,[321],"The current study focuses on clinical validation of efficacy of nutraceutical product in relieving stress and functional dyspepsia symptoms in adults for gut health. The effect of these nutraceuticals not only targets the physical symptoms but also enhances overall well-being. Improved digestive health leads to better nutrient absorption, which is essential for energy levels and immune function. Reduced stress levels contribute to better sleep quality, cognitive function, and emotional stability.",[522,26,446],"Stress",[524,26,446],"stress","2024-08-22",{"date":527,"type":40},"2024-08-23",{"date":529,"type":20},"2024-09-05",{"date":531,"type":20},"2024-12-28",{"name":533,"class":466},"Herbolab India Pvt. Ltd.",{"id":535,"slug":536,"hasResults":11,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":291,"enrollmentInfo":541,"targetDuration":4,"studyType":21,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":4},"100367822","phase-3-efficacy-of-oral-aroeira-schinus-terebinthifolia-raddi-compared-to-omeprazole-in-dyspeppsia-100367822","NCT04069286","EFFICACY OF ORAL AROEIRA (Schinus Terebinthifolia Raddi) COMPARED TO OMEPRAZOLE IN DYSPEPPSIA","EFFICACY OF ORAL AROEIRA (Schinus Terebinthifolia Raddi) COMPARED TO OMEPRAZOLE IN PARTICIPANTS DIAGNOSED WITH FUNCTIONAL DYSPEPPSIA: A RANDOMIZED AND DOUBLE-BLIND STUDY","To be eligible to participate in this study, an individual must meet all of the following criteria:\n\nReport of at least 1 of the 5 dyspeptic symptoms, with onset more than 6 months ago, with at least least 3 months in duration, according to the ROME IV Classification criteria:\n\n* Nausea;\n* Heartburn;\n* Epigastric pain;\n* Abdominal discomfort aggravated\u002Frelieved by meals;\n* Feeling of early satiety.\n\nManifestation of the desire to participate in the study in a free and informed manner.\n\nAge range between 18 and 80 years old;\n\nAbility and desire to use an acceptable method of contraception listed below during the study and until the last follow-up visit:\n\n* Women - condoms, oral, topical, injectable or implantable contraceptive medications, Intrauterine Devices (IUDs) with or without hormones and true abstinence that is aligned with the participant's preferred and usual lifestyle (periodic abstinence \\[e.g., methods of table, ovulation, symptothermic, post-ovulation\\], declaration of abstinence during the period of study or coitus interruptus are not acceptable methods of true abstinence).\n* Women - will be referred to a gynecologist for screening and better definition of the method;\n* Men - guidance on condom use.",{"count":542,"type":20},474,[124],"This is a prospective, randomized, double - blind study of 474 male and female volunteers with dyspeppsia diagnosed at the Oswaldo Cruz University Hospital Gastroenterology Outpatient Clinic from March 2025 to March 2027.\n\nHypothesis:\n\nAs a non-inferiority study, the hypothesis is that the use of oral Aroeira (Schinus terebinthifolia Raddi) for the treatment of participants diagnosed with functional dyspepsia efficacy not inferior to therapy based on the use of omeprazole.",[26],"2024-04-24",{"date":548,"type":40},"2024-04-29",{"date":550,"type":20},"2025-03",{"date":552,"type":20},"2027-03",{"name":554,"class":466},"Infan Industria Quimica Farmaceutica Nacional",{"id":556,"slug":557,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":563,"targetDuration":4,"studyType":21,"phases":565,"briefSummary":566,"conditions":567,"keywords":573,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":4},"100516284","relief-pathway-in-patients-with-upper-abdominal-pain-100516284","NCT06002516","RELIEF-pathway in Patients With Upper Abdominal Pain","The RELIEF-pathway in Patients With Upper Abdominal Pain; an Open-label Multicenter Randomized Controlled Trial","RELIEF","Inclusion Criteria:\n\n* Patients between 18 and 70 years old.\n* First referral due to upper abdominal pain (UAP) and symptoms due to Functional dyspepsia (ICPC code 87.02), Irritable Bowel syndrome (ICPC 93.0) or uncomplicated symptomatic cholecystolithiasis (ICPC 98.03).\n* Proficient in reading and understanding of the Dutch language.\n* Referred to the outpatient clinic of gastroenterology or surgery.\n* Providing informed consent.\n\nExclusion Criteria:\n\n* If the following alarm symptoms are reported in the referral letter by the GP: weight loss, persistent vomiting, dysphagia, jaundice, hematemesis, melena, haematochezia, or anaemia.\n* Any other direct or indirect signs of cancer or upper GI tract bleeding.\n* Patients with a first or second-degree relative with a history of upper GI tract malignant neoplasm.\n* Patients with a history of complicated cholecystolithiasis.\n* A history of or current malignancy (except SCC or BCC of the skin).\n* Pregnancy;\n* Expected short life span of less than 12 months.\n* Known cirrhosis of the liver\n* Current schizophrenia, memory deficiency, or any other disorder that predispose them to unreliable questionnaire responses;\n* Mentally incompetent;",{"count":564,"type":20},471,[321],"Upper abdominal pain (UAP) is a common symptom and frequently the reason to visit the hospital. The prevalence of epigastric pain in the Dutch population is estimated to be as high as 37%. Moreover, Dutch hospitals yearly record \\>100.000 diagnoses related to UAP. In most patients, UAP can be attributed to symptomatic (functional) dyspepsia (FD), Irritable Bowel Syndrome (IBS) or uncomplicated gallstone disease (cholecystolithiasis), with a prevalence in the general population of 20-30%, 20%, and 6-9%, respectively. However, these conditions may have overlapping symptom patterns and generally affect similar populations. which contributes to ineffective (diagnostic) interventions. Patients are generally not aware of the similarity of symptoms and the poor outcome of some treatments.\n\nEducation positively influences patients' self-management and health judgment. In a recent open-label, multicentre trial the effectiveness of web-based patients' education is applied to reduce overuse of upper gastrointestinal endoscopies in patients with dyspepsia. This study illustrated that an web-based education tool safely reduced 40% in upper gastrointestinal endoscopies. Lifestyle interventions (such as change of diet and\u002For physical activity) are widely incorporated in treatment programs for cardio-vascular diseases including diabetes mellitus and obesity. An web-based education tool on upper abdominal pain and other complaints combined with a lifestyle interventions for patients may be an effective treatment option for this large group of patients.\n\nThis study investigates the potential of an individualized web-based education tool as intervention for patients with functional dyspepsia, irritable bowel syndrome and uncomplicated symptomatic cholecystolithiasis with the possibility to visit the Prevention and Lifestyle clinic (RELIEF pathway). The RELIEF pathway aims to reduce unnecessary health care utilization and, secondly, to maintain and improve quality of life by educating patients on lifestyle improvement.",[568,569,26,220,570,571,451,572],"Abdominal Pain","Gallstone; Colic","Health Care Utilization","Patient Reported Outcomes","Decision Aid",[574,575],"Abdominal pain","Health care utilization","2023-08-15",{"date":578,"type":40},"2023-08-21",{"date":580,"type":20},"2024-05-01",{"date":582,"type":20},"2027-05-01",{"name":584,"class":47},"Radboud University Medical Center"]